# Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

> **NCT04413734** · PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 120 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma by AJCC V8 Stage

## Interventions

- **DRUG:** Combination therapy
- **DRUG:** Mono-chemotherapy

## Key facts

- **NCT ID:** NCT04413734
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-22
- **Primary completion:** 2022-04-22
- **Final completion:** 2024-04-22
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04413734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04413734, "Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04413734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*